TY - JOUR
T1 - Barriers to Pancreatic Clinical Trials Enrollment
AU - Pant, Shubham
AU - Lee, Michael S.
PY - 2020/10/9
Y1 - 2020/10/9
N2 - Pancreatic cancer is the third leading cause of cancer mortality in the United States, causing an estimated 47,050 deaths in the year 2020, and had the lowest 5-year relative survival of any cancer type diagnosed in 2009-2015, at only 9%. In light of this limited prognosis, consensus guidelines from ASCO and NCCN recommend that patients be informed about and/or managed in clinical trials. However, only 4.16% of patients with pancreatic cancer ultimately enrolled in clinical trials in 2014, while enrollment to existing trials is noted to be unacceptably slow.
AB - Pancreatic cancer is the third leading cause of cancer mortality in the United States, causing an estimated 47,050 deaths in the year 2020, and had the lowest 5-year relative survival of any cancer type diagnosed in 2009-2015, at only 9%. In light of this limited prognosis, consensus guidelines from ASCO and NCCN recommend that patients be informed about and/or managed in clinical trials. However, only 4.16% of patients with pancreatic cancer ultimately enrolled in clinical trials in 2014, while enrollment to existing trials is noted to be unacceptably slow.
UR - http://www.scopus.com/inward/record.url?scp=85094119876&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85094119876&partnerID=8YFLogxK
U2 - 10.46883/ONC.2020.3410.0407.1
DO - 10.46883/ONC.2020.3410.0407.1
M3 - Comment/debate
C2 - 33090379
AN - SCOPUS:85094119876
SN - 0890-9091
VL - 34
JO - Oncology (Williston Park, N.Y.)
JF - Oncology (Williston Park, N.Y.)
IS - 10
ER -